期刊文献+

临床药师参与左心室辅助装置植入术后感染治疗的病例分析 被引量:1

Case analysis of clinical pharmacist participating in the treatment of infection after left ventricular assist device implantation
下载PDF
导出
摘要 目的:为临床左心室辅助装置植入术后感染患者的治疗提供参考依据与用药经验。方法:临床药师参与1例左心室辅助装置植入术后感染的治疗,协助医师制定给药方案,密切关注药物相互作用,提出个体化用药建议,并对患者进行药学监护。结果:临床药师根据血药浓度监测结果及时调整给药方案,治疗效果显著。结论:临床药师运用专业的药学知识与思维,协助治疗过程,保证了疗效,减少了不良反应的发生,体现了临床药师在多学科诊疗中的积极作用。 Objective:To provide reference basis and medication experience for the treatment of patients with infection after left ventricular assist device implantation.Methods:A clinical pharmacist participated in the consultation treatment of a case of infection after the implantation of the left ventricular assist device,assisted physicians in formulating drug administration plan,proposed individualized medication recommendations,and provided pharmaceutical care for the patient.Results:The therapeutic effect was significant after the administration plan was adjusted in time by the clinical pharmacist according to the results of the monitoring of blood concentrations.Conclusion:Clinical pharmacists use their professional pharmaceutical knowledge and thinking to assist physicians in the treatment process,which can ensure the curative effect,reduce the occurrence of adverse reactions,reflect the positive role of clinical pharmacists in multidisciplinary diagnosis and treatment.
作者 李雪 张寒娟 于丽 LI Xue;ZHANG Hanjuan;YU Li(Department of Pharmacy,the Seventh People’s Hospital of Zhengzhou,Zhengzhou 450016,China)
出处 《上海医药》 CAS 2021年第17期67-69,78,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 左心室辅助装置 心力衰竭 伏立康唑 left ventricular assist devices heart failure voriconazole
  • 相关文献

参考文献6

二级参考文献24

  • 1重症患者侵袭性真菌感染诊断与治疗指南(2007)[J].中华内科杂志,2007,46(11):960-966. 被引量:426
  • 2无.肺真菌病诊断和治疗专家共识[J].中华结核和呼吸杂志,2007,30(11):821-834. 被引量:603
  • 3Holbrook A M, Pereira J A, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions[J]. Arch Intern Med, 2005, 165(10):1095-1106.
  • 4Kunze K L, Wienkers L C, Thummel K E, et al. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies[J]. Drug Metab Dispos, 1996, 24(4):414-421.
  • 5Kaminsky L S, Zhang Z Y. Human P450 metabolism of warfarin[J]. Pharmacol Ther, 1997, 73(1):67-74.
  • 6van der Elst K C, Span L F, van Hateren K, et al. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole[J]. Antimicrob Agents Chemother, 2013, 57(10):4999-5004.
  • 7Andes D, Paseual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications[J]. Antimicrob Agents Chemother, 2009, 53(1):24-34.
  • 8Niwa T, Inoue-Yamamoto S, Shiraga T, et al. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2EI activities in human liver microsomes[J]. Biol Pharm Bull, 2005, 28(9):1813-1816.
  • 9Yamamoto H, Habu Y, Yano I, et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin[J]. Biol Pharm Bull, 2014, 37(12):1990-1993.
  • 10Miura M, Takahashi N, Kanno S, et al. Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient[J]. Clin Chim Acta, 2011,412(21-22):2002-2006.

共引文献174

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部